Clinical trial
Phase 2 Study to Evaluate the Efficacy & Safety of Brilacidin Oral Rinse Administered Daily for 7 Weeks in Attenuating Oral Mucositis in Patients With Head & Neck Cancer Receiving Chemoradiation
NCT02324335 is registered in ClinicalTrials.gov with Innovation Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study to Evaluate the Efficacy & Safety of Brilacidin Oral Rinse Administered Daily for 7 Weeks in Attenuating Oral Mucositis in Patients With Head & Neck Cancer Receiving Chemoradiation
- Lead sponsor
- Innovation Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 14, 2014
- Completion date
- November 22, 2017
- Enrollment
- 61 (actual)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.